SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448% % 273%
Debt-to-equity 27% % -89%
Return On Assets -75% % 58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142,442,239 shares 102%
Common Stock, Shares, Outstanding 125,078,525 shares 94%
Entity Public Float $68,573,913 USD 54%
Common Stock, Value, Issued $12,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 108,396,260 shares 59%
Weighted Average Number of Shares Outstanding, Diluted 108,396,260 shares 59%

Income Statement

Label TTM Value / Value Unit Change %
Costs and Expenses $26,937,000 USD -18%
Operating Income (Loss) $26,937,000 USD 18%
Nonoperating Income (Expense) $995,000 USD 102%
Net Income (Loss) Attributable to Parent $25,942,000 USD 20%
Earnings Per Share, Basic 0 USD/shares 61%
Earnings Per Share, Diluted 0 USD/shares 61%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $44,320,000 USD 111%
Assets, Current $49,051,000 USD 104%
Operating Lease, Right-of-Use Asset $556,000 USD 8.4%
Goodwill $1,914,000 USD 0%
Assets $51,555,000 USD 95%
Accounts Payable, Current $2,305,000 USD -49%
Employee-related Liabilities, Current $1,423,000 USD -20%
Accrued Liabilities, Current $3,021,000 USD -45%
Liabilities, Current $5,925,000 USD -44%
Operating Lease, Liability, Noncurrent $0 USD
Liabilities $5,925,000 USD -44%
Retained Earnings (Accumulated Deficit) $267,330,000 USD -11%
Stockholders' Equity Attributable to Parent $45,630,000 USD 187%
Liabilities and Equity $51,555,000 USD 95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,070,000 USD 16%
Net Cash Provided by (Used in) Financing Activities $23,581,000 USD -12%
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 125,078,525 shares 94%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,511,000 USD -8.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44,420,000 USD 110%
Deferred Tax Assets, Valuation Allowance $20,866,000 USD 11%
Deferred Tax Assets, Gross $21,066,000 USD 11%
Operating Lease, Liability $599,000 USD 4%
Lessee, Operating Lease, Liability, to be Paid $635,000 USD 3.8%
Operating Lease, Liability, Current $599,000 USD 4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $477,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $477,000 USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $36,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $14,116,000 USD 16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Operating Lease, Payments $800,000 USD 60%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $200,000 USD 8.7%
Share-based Payment Arrangement, Expense $1,882,000 USD 11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%